Induction of Mitogen-Activated Protein Kinases Is Proportional to the Amount of Pressure Overload

Pressure overload has been shown to induce mitogen activated protein kinases (MAPKs) and reactivate the atrial natriuretic factor in the heart. To test the sensitivity of these signals to pressure overload, we assayed the activity of MAPKs extracellular signal–regulated kinase, c-Jun N-terminal kinase 1, and p38 in protein lysates from the left ventricle (LV) or white blood cells (WBC) isolated from aortic banded mice with varying levels of pressure overload. In separated mice we measured atrial natriuretic factor mRNA levels by Northern blotting. As expected, a significant induction of atrial natriuretic factor mRNA levels was observed after aortic banding, and it significantly correlated with the trans-stenotic systolic pressure gradient but not with the LV weight:body weight ratio. In contrast, a significant correlation with systolic pressure gradient or LV weight:body weight ratio was observed for all of the MAPK activity detected in LV samples or WBCs. Importantly, LV activation of MAPKs significantly correlated with their activation in WBCs from the same animal. To test whether MAPK activation in WBCs might reflect uncontrolled blood pressure levels in humans, we assayed extracellular signal–regulated kinase, c-Jun N-terminal kinase 1, and p38 activation in WBCs isolated from normotensive volunteers, hypertensive patients with controlled blood pressure values, or hypertensive patients with uncontrolled blood pressure values. Interestingly, in hypertensive patients with controlled blood pressure values, LV mass and extracellular signal–regulated kinase phosphorylation were significantly reduced compared with those in hypertensive patients with uncontrolled blood pressure values. These results suggest that MAPKs are sensors of pressure overload and that extracellular signal–regulated kinase activation in WBCs might be used as a novel surrogate biomarker of uncontrolled human hypertension.

[1]  G. Esposito,et al.  Cardiac hypertrophy: role of G protein-coupled receptors. , 2002, Journal of cardiac failure.

[2]  J. Ross,et al.  Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Böyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[4]  P. Insel,et al.  Peripheral adrenergic receptors in hypertension. , 1990, Hypertension.

[5]  J Ross,et al.  Molecular and physiological alterations in murine ventricular dysfunction. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Indolfi,et al.  Transient and reversible deoxyribonucleic acid damage in human left ventricle under controlled ischemia and reperfusion. , 2004, Journal of the American College of Cardiology.

[7]  M. Chiariello,et al.  Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize beta-adrenergic receptor function in heart failure. , 2006, Vascular pharmacology.

[8]  References , 1971 .

[9]  W. Koch,et al.  Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress , 2002, Circulation.

[10]  M. Marber,et al.  Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. , 2007, Pharmacology & therapeutics.

[11]  R. Feldman Insulin‐mediated sensitization of adenylyl cyclase activation , 1993, British journal of pharmacology.

[12]  Marc A Pfeffer,et al.  Controversies in ventricular remodelling , 2006, The Lancet.

[13]  Hyung-Suk Kim,et al.  Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. , 2006, The Journal of clinical investigation.

[14]  H. Rockman,et al.  JNK1 is required to preserve cardiac function in the early response to pressure overload. , 2006, Biochemical and biophysical research communications.

[15]  W. Koch,et al.  Cardiac Overexpression of a Gq Inhibitor Blocks Induction of Extracellular Signal–Regulated Kinase and c-Jun NH2-Terminal Kinase Activity in In Vivo Pressure Overload , 2001, Circulation.

[16]  K. Chien,et al.  Transcriptional regulation during cardiac growth and development. , 1993, Annual review of physiology.

[17]  G. Dorn,et al.  Genetic Factors in Cardiac Hypertrophy , 2004, Annals of the New York Academy of Sciences.

[18]  W. Ganong,et al.  Extra-atrial expression of the gene for atrial natriuretic factor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[20]  C. Rackley,et al.  Measurement of Left Ventricular Wall Thickness and Mass by Echocardiography , 1972, Circulation.